Genetic factors affecting patient responses to pancreatic cancer treatment
Author:
Open Access
- 1 January 2016
- journal article
- review article
- Published by Hellenic Society of Gastroenterology in Annals of Gastroenterology
- Vol. 29 (4) , 466-476
Abstract
Cancer of the exocrine pancreas is a malignancy with a high lethal rate. Surgical resection is the only possible curative mode of treatment. Metastatic pancreatic cancer is incurable with modest results from the current treatment options. New genomic information could prove treatment efficacy. An independent review of PubMed and ScienceDirect databases was performed up to March 2016, using combinations of terms such pancreatic exocrine cancer, chemotherapy, genomic profile, pancreatic cancer pharmacogenomics, genomics, molecular pancreatic pathogenesis, and targeted therapy. Recent genetic studies have identified new markers and therapeutic targets. Our current knowledge of pancreatic cancer genetics must be further advanced to elucidate the molecular basis and pathogenesis of the disease, improve the accuracy of diagnosis, and guide tailor-made therapies.Keywords
This publication has 77 references indexed in Scilit:
- ATM Mutations in Patients with Hereditary Pancreatic CancerCancer Discovery, 2012
- Nucleobase Transport by Human Equilibrative Nucleoside Transporter 1 (hENT1)Journal of Biological Chemistry, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progressionCancer and Metastasis Reviews, 2010
- PALB2 mutations in European familial pancreatic cancer familiesClinical Genetics, 2010
- SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic CancerClinical Cancer Research, 2009
- Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patientsBritish Journal of Cancer, 2009
- Analysis of mortality rates for pancreatic cancer across the worldHPB, 2008
- Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and SurvivalClinical Cancer Research, 2006
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003